There is now a better understanding of the differential effectiveness of nonpharmaceutical interventions (NPIs) in containing the spread of SARS-CoV-2 in different regions, social parameters, and phases of the pandemic. However, the medium- and long-term impact of these NPIs remains poorly understood.


The medium- and long-term impact of non-pharmaceutical interventions used during the COVID-19 pandemic on respiratory infections such as respiratory syncytial viruses, influenza viruses, and pneumococci remains poorly understood, but plays a critical role in assessing the overall burden of disease following NPIs. RESPINOW aims to develop an integrated model for simulating the transmission of various respiratory infections and the collateral effects of NPIs on the medium- and long-term burden of disease. To support the development of novel models of the medium- and long-term spread of respiratory disease following NPIs, a population-based cohort will be assessed for their immunity to RSV and influenza, as well as for their contact behavior following a pandemic in future years. To this end, the Multiplex Immunoassays group at the NMI will further develop antibody assays against RSV and influenza viruses to provide seroprevalence data on spread in the population.

More information can be found here:



01.05.2022 - 30.04.2025


Dr. Nicole Schneiderhan-Marra

Head of Pharma & Biotech